Introducing PEP 2.1

The additions run the length of the evidence ladder, from an approved therapy with randomized trials behind it to peptides that exist mostly in one research tradition. PEP tells you which is which.

• Teriparatide: recombinant parathyroid hormone 1-34, the most studied compound in this round, with randomized controlled trials in the corpus.
• ARA-290: cibinetide, an 11-amino-acid peptide modeled on erythropoietin's helix B, with phase 2 clinical data.
• Glutathione: the tripeptide the cell uses as its main redox buffer, and one of the most asked-about compounds we had not yet covered.
• 5-Amino-1MQ: not a peptide but an NNMT inhibitor, studied so far in animal and cell models.
• Dermorphin: the frog-skin heptapeptide behind a line of opioid receptor research.
• Five Khavinson bioregulators: Bronchogen, Cardiogen, Chonluten, Cortagen, and Pinealon. Short synthetic peptides from the Russian bioregulator program, studied for tissue-specific gene expression, with evidence that is mostly animal and in vitro.

Several compounds in this round are widely discussed and thinly studied. Every new compound enters the knowledge base with its evidence level recorded, and PEP answers in that context. Where the data is animal or in vitro, it says so before it says anything else.

Ask what the research says about Pinealon and cognition. PEP answers from the animal and mechanistic studies that exist, describes what each one measured, and says plainly that indexed human data is thin. That is the answer the literature supports, and it is the one you get.

More compounds, sharper retrieval, and the next major release as the model grows.